Biologic treatment of inflammatory bowel disease in Poland, 2012–2020: nationwide data

Abstract

To the best of our knowledge, this article is the first to describe the population of Polish patients suffering from inflammatory bowel diseases (IBDs) and treated with innovative biologic drugs, which are the best treatment options known for patients with moderate to severe disease courses. Using administrative data, we estimate and discuss the significant differences in the use of biologic drugs across different regions of the country. We also show a higher treatment rate for men, compared to women, as well as a high and growing rate for the youngest population. Access to modern therapies is crucial for improving quality of life for the substantially growing population of IBD patients. We believe our work will be a helpful reference for evaluating the current situation of those patients and for predicting future demands.

Association of the ILR1 and FAS genes variants with a primary non-response to Anti-TNF therapy in Crohn's disease patients

“…Herein we aimed to verify this discovery through a study involving a larger group of 196 patients with CD. In our study group, the number of male patients was higher than female (77 vs. 119, Table 1), which reflects the observation made by Kucha et al in Polish nationwide data for 2012-2020 that women receive biological treatment for both the CD and UC significantly less frequently than men [16]. We assessed 5 loci identified in 2020 (rs7539036, rs2041747, rs5746053, rs1143634, rs7896789) in the FCGR3A, IL1R, TNFRSF1B, IL1 and FAS genes, respectively.…”

Savings in social expenditures for work incapacity in patients with inflammatory bowel disease depend on access to innovative therapies in Poland

“…Services associated with innovative treatment of CD or UC were identified in the NFZ service database with respect to specific products covered by the NFZ contracts. Detailed methodology on NFZ data use has been described by Zagorowicz et al [6] and Kucha et al [11].…”

Relation between symptoms of insomnia, depression, sleep quality, anti-tumor necrosis factor therapy and disrupted circadian clock genes’ expression in inflammatory bowel disease

“…Anti tumor necrosis factor (TNF) therapy is effective and has a good safety profile. 21- 23 It does not appear to cause sleep disruptions, with some studies showing it may even improve sleep quality. 3,24, 25 Its influence on the clock gene expression in IBD has not been extensively studied.…”